Literature DB >> 15846083

p53 gain-of-function: tumor biology and bioinformatics come together.

Eugene V Koonin1, Igor B Rogozin, Galina V Glazko.   

Abstract

p53 is typically viewed as a tumor suppressor. However, many missense somatic and germline mutations in the p53 gene cause gain-of-function whereby p53 acquires novel biochemical activities, such as the ability to transactivate transcription of new genes or to mediate new regulatory protein-protein interactions. Several recent studies show that at least some gain-of-function mutations of p53 are biologically relevant leading to a change in the tumor phenotype. Independent bioinformatic analysis of somatic mutation spectra of the p53 gene yields three lines of evidence supporting the notion that gain-of-function could be the prevalent mode of p53 evolution in tumors. (1) The hotspots in the p53 gene show signs of intensive positive selection. (2) The hotspots are located primarily in functionally important motifs of the DNA-binding domain of p53 which are highly conserved in interspecies evolution. (3) The spectra of hotspots significantly differ among various tumor types and the germline (Li-Fraumeni syndrome); in addition to the hotspots shared by the germline and some of the tumors, many are tumor-specific. The latter observation suggests an unexpected level of complexity of p53 evolution in tumors, with distinct novel function gained in different tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15846083     DOI: 10.4161/cc.4.5.1691

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  6 in total

1.  Dipeptide analysis of p53 mutations and evolution of p53 family proteins.

Authors:  Qiang Huang; Long Yu; Arnold J Levine; Ruth Nussinov; Buyong Ma
Journal:  Biochim Biophys Acta       Date:  2013-04-10

2.  Molecular population genetics of PCSK9: a signature of recent positive selection.

Authors:  Keyue Ding; Iftikhar J Kullo
Journal:  Pharmacogenet Genomics       Date:  2008-03       Impact factor: 2.089

3.  Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma.

Authors:  Olivier Ayrault; Michael D Godeny; Christopher Dillon; Frederique Zindy; Patrick Fitzgerald; Martine F Roussel; Helen M Beere
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-23       Impact factor: 11.205

4.  The Forty-Sixth Euro Congress on Drug Synthesis and Analysis: Snapshot .

Authors:  Pavel Mucaji; Atanas G Atanasov; Andrzej Bak; Violetta Kozik; Karolina Sieron; Mark Olsen; Weidong Pan; Yazhou Liu; Shengchao Hu; Junjie Lan; Norbert Haider; Robert Musiol; Jan Vanco; Marc Diederich; Seungwon Ji; Jan Zitko; Dongdong Wang; Danica Agbaba; Katarina Nikolic; Slavica Oljacic; Jelica Vucicevic; Daniela Jezova; Anna Tsantili-Kakoulidou; Fotios Tsopelas; Constantinos Giaginis; Teresa Kowalska; Mieczyslaw Sajewicz; Jerzy Silberring; Przemyslaw Mielczarek; Marek Smoluch; Izabela Jendrzejewska; Jaroslaw Polanski; Josef Jampilek
Journal:  Molecules       Date:  2017-10-28       Impact factor: 4.411

5.  Mutational hotspots in the TP53 gene and, possibly, other tumor suppressors evolve by positive selection.

Authors:  Galina V Glazko; Vladimir N Babenko; Eugene V Koonin; Igor B Rogozin
Journal:  Biol Direct       Date:  2006-01-31       Impact factor: 4.540

6.  Signs of positive selection of somatic mutations in human cancers detected by EST sequence analysis.

Authors:  Vladimir N Babenko; Malay K Basu; Fyodor A Kondrashov; Igor B Rogozin; Eugene V Koonin
Journal:  BMC Cancer       Date:  2006-02-09       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.